TSC22D1

Across TCGA pan-cancer cohorts, TSC22D1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TSC22D1 data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TSC22D1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TSC22D1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where TSC22D1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.277	1.000	.008	43	view →
LSCC	DFS	Median	All	0.594	0.815	.006	17	view →
LUAD	DFS	Tertile	All	0.738	0.450	.013	9	view →
CCRCC	DFS	Median	III,IV	0.873	0.565	.007	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TSC22D1–HNSC (OS)

Open the HNSC breakdown →